Heron Therapeutics (NASDAQ:HRTX - Get Free Report) had its price target decreased by Needham & Company LLC from $5.00 to $4.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has a "buy" rating on the biotechnology company's stock. Needham & Company LLC's price objective indicates a potential upside of 234.73% from the company's current price.
Heron Therapeutics Stock Performance
Shares of HRTX stock traded down $0.09 during trading hours on Wednesday, reaching $1.20. The company had a trading volume of 2,343,391 shares, compared to its average volume of 2,419,979. The business has a fifty day moving average price of $1.86 and a 200-day moving average price of $2.54. Heron Therapeutics has a one year low of $0.53 and a one year high of $3.93.
Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.03). The firm had revenue of $32.81 million during the quarter, compared to analysts' expectations of $36.40 million. During the same quarter last year, the business earned ($0.17) earnings per share. As a group, equities research analysts expect that Heron Therapeutics will post -0.08 earnings per share for the current year.
Hedge Funds Weigh In On Heron Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of HRTX. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Heron Therapeutics in the 1st quarter worth $90,000. BNP Paribas Financial Markets lifted its position in Heron Therapeutics by 80.7% during the first quarter. BNP Paribas Financial Markets now owns 51,296 shares of the biotechnology company's stock valued at $142,000 after purchasing an additional 22,904 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new position in Heron Therapeutics during the first quarter valued at $32,000. Headlands Technologies LLC purchased a new position in Heron Therapeutics during the first quarter valued at $30,000. Finally, State Board of Administration of Florida Retirement System lifted its position in Heron Therapeutics by 51.4% during the first quarter. State Board of Administration of Florida Retirement System now owns 40,705 shares of the biotechnology company's stock valued at $113,000 after purchasing an additional 13,811 shares in the last quarter. 80.01% of the stock is currently owned by hedge funds and other institutional investors.
Heron Therapeutics Company Profile
(
Get Free Report)
Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
See Also
Before you consider Heron Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Heron Therapeutics wasn't on the list.
While Heron Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
